Surgery improves overall and cancer-specific survival of rare urinary cancers; population - based study
Abdullah Al-Danakh1, Mohammed Safi2, Mohammed Al-Radhi3
1Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, 116021, Zhongshan Road No. 222, Dalian, China.
Abstract:
Numerous rare urinary tract (UT) cancers lack adequate understanding of survival and therapeutic options, and nearly all responses to systemic therapy are unsatisfactory, yet clinical research is scarce.
Methods:
Between 2010 and 2015, a total of (14,622 patients) with uncommon UT cancer (62.5%) in the overall survival (OS) group and (37.5%) in the cancer specific survival (CSS)group were identified in the SEER database. multimodality therapeutic approach on OS and CSS were compared.
Results:
In uncommon UT malignancies, OS outperformed CSS in the locoregional stage (P < 0.05), but not in the distant stage (P = 0.34). Non-performed surgery had poor survival in both OS (HR 1.647; 95% CI (1.461-1.856)) and CSS (HR 1.573; 95% CI (1.399-1.769)) respectively (P < 0.05). There were no significant differences in survival in the CSS group between those who received or did not obtain chemotherapy.
Conclusions:
The OS group survives substantially longer than the CSS group in the locoregional stage, but not at the distant stage. While both the OS and CSS groups of the locoregional stage were linked with improved survival after surgery, chemotherapy treatment decreased OS but not CSS in patients with uncommon urological cancers. There were no differences in radiation between the OS and CSS.
Insights
For rare urinary tract cancers, overall survival is better than cancer-specific survival in early stages. Surgery improves outcomes, but chemotherapy
Area of Science:
- Urology
- Oncology
- Cancer Research
Background:
- Rare urinary tract (UT) cancers have limited understanding regarding survival and treatment.
- Current systemic therapy responses are generally unsatisfactory, with scarce clinical research.
Purpose of the Study:
- To compare overall survival (OS) and cancer-specific survival (CSS) in patients with uncommon UT cancers.
- To evaluate the impact of multimodality therapeutic approaches on OS and CSS.
Main Methods:
- Utilized the SEER database to identify 14,622 patients with uncommon UT cancer from 2010-2015.
- Compared outcomes between overall survival (OS) and cancer-specific survival (CSS) groups.
- Assessed the effect of surgical intervention and chemotherapy on survival rates.
Main Results:
- OS was superior to CSS in the locoregional stage (P < 0.05), but not in the distant stage (P = 0.34).
- Lack of surgery was associated with significantly poorer survival in both OS (HR 1.647) and CSS (HR 1.573) groups (P < 0.05).
- Chemotherapy showed no significant difference in survival for the CSS group.
Conclusions:
- Overall survival is significantly longer than cancer-specific survival in the locoregional stage for uncommon UT cancers.
- Surgery is linked to improved survival in both OS and CSS for locoregional disease.
- Chemotherapy negatively impacted OS but not CSS in this patient cohort.
Related Concept Videos
01:25Urinary Tract Calculi VI: Surgical Management
01:21Cancer Survival Analysis
01:30Urinary Tract Calculi III: Medical Management